INmune Bio financials
$1.96−2.00%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 |
|---|---|---|---|---|---|---|---|
| Revenue | $50.0K | $14.0K | $155.0K | $374.0K | $181.0K | $11.0K | — |
| Gross profit | $50.0K | $14.0K | $155.0K | $374.0K | $181.0K | $11.0K | — |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — |
| Operating income | -$30.9M | -$42.6M | -$29.7M | -$26.0M | -$30.3M | -$12.2M | -$9.3M |
| Net income | -$45.9M | -$42.1M | -$30.0M | -$27.3M | -$30.3M | -$12.1M | -$7.7M |
| Net margin | −91866.0% | −300585.7% | −19360.0% | −7299.2% | −16762.4% | −109990.9% | — |
| Diluted EPS | $-1.86 | $-2.11 | $-1.67 | $-1.52 | $-1.88 | $-1.01 | $-0.75 |
| EBITDA | -$30.8M | -$42.6M | -$29.7M | -$26.0M | -$30.3M | -$12.2M | -$9.3M |
| Operating cash flow | -$22.6M | -$33.4M | -$12.0M | -$22.7M | -$28.5M | -$10.0M | -$5.4M |
| Free cash flow | -$23.6M | -$33.4M | -$12.0M | -$22.7M | — | — | — |
| Diluted shares | 24.8M | 19.9M | 18.0M | 17.9M | 16.1M | 12.0M | 10.3M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $24.8M | $20.9M | $35.8M | $52.2M | $74.8M | $22.0M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $0.00 | $0.00 | $9.9M | $14.7M | $14.5M | $0.00 |
| Total assets | $32.4M | $39.6M | $57.0M | $81.8M | $99.9M | $40.7M |
| Total liabilities | $8.8M | $7.5M | $18.9M | $21.7M | $19.7M | $1.9M |
| Shareholders' equity | $23.5M | $32.1M | $37.3M | $60.1M | $80.2M | $38.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology